Agenus (AGEN) Net Income towards Common Stockholders (2010 - 2026)
Agenus' (AGEN) quarterly Net Income towards Common Stockholders came in at $39.2 million in Q1 2026, up 254.71% year-on-year from $11.0 million in Q1 2025, and up 468.43% quarter-over-quarter from -$10.6 million in Q4 2025.
Agenus (AGEN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Agenus' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $39.2 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 254.71% year-over-year to $39.2 million in Q1 2026; TTM through Mar 2026 was $64.4 million, a 133.75% increase from a year earlier, with the FY2025 full-year figure at -$101000.0, up 99.96% from the prior year.
- Net Income towards Common Stockholders climbed to $39.2 million in Q1 2026 per AGEN's latest filing, from -$10.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $63.9 million in Q3 2025 and bottomed at -$71.1 million in Q4 2022.
- The 5-year median for Net Income towards Common Stockholders is -$48.4 million (2022), against an average of -$38.5 million.
- Across the five-year window, Net Income towards Common Stockholders tumbled 130.41% in 2022 and surged 254.71% in 2026, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$71.1 million in 2022, then surged by 34.86% to -$46.3 million in 2023, then grew by 0.93% to -$45.9 million in 2024, then surged by 76.84% to -$10.6 million in 2025, then soared by 468.43% to $39.2 million in 2026.
- Per Business Quant, the three latest AGEN Net Income towards Common Stockholders figures stand at $39.2 million (Q1 2026), -$10.6 million (Q4 2025), and $63.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Agenus | 222.90 Mn | 222.90 Mn | 33.74 Mn | 39.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.17 Mn |
| Dec 31, 2025 | -10.63 Mn |
| Sep 30, 2025 | 63.86 Mn |
| Jun 30, 2025 | -28.01 Mn |
| Mar 31, 2025 | -25.32 Mn |
| Dec 31, 2024 | -45.91 Mn |
| Sep 30, 2024 | -66.44 Mn |
| Jun 30, 2024 | -53.14 Mn |
| Mar 31, 2024 | -61.94 Mn |
| Dec 31, 2023 | -46.34 Mn |
| Sep 30, 2023 | -62.25 Mn |
| Jun 30, 2023 | -69.07 Mn |
| Mar 31, 2023 | -68.31 Mn |
| Dec 31, 2022 | -71.15 Mn |
| Sep 30, 2022 | -54.28 Mn |
| Jun 30, 2022 | -46.49 Mn |
| Mar 31, 2022 | -48.38 Mn |
| Dec 31, 2021 | -65.56 Mn |
| Sep 30, 2021 | 178.50 Mn |
| Jun 30, 2021 | -83.34 Mn |